SAN DIEGO, May 25, 2017 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company
developing novel oncology and drug-delivery therapies will be
presenting a corporate overview at three upcoming investor
conferences.
Laurie Stelzer, senior vice
president and chief financial officer will present at the Jefferies
2017 Global Healthcare Conference in New
York on June 8 at 1:30 p.m. ET / 10:30 a.m.
PT, and at the JMP Securities 2017 Life Sciences Conference
in New York on June 20 at 11:00 a.m.
ET / 8:00 a.m. PT.
On Tuesday, June 13, Dr.
Helen Torley, president and chief
executive officer will present at the Goldman Sachs 38th
Annual Global Healthcare Conference in Rancho Palos Verdes at 5:00 p.m. ET / 2:00 p.m.
PT.
Webcasts for the presentations can be accessed through the
"Investors" section of www.halozyme.com, and a recording will be
made available for 90 days following each event. To access a live
webcast, please visit Halozyme's website approximately 15 minutes
prior to the presentation to register and download any necessary
audio software.
About Halozyme
Halozyme Therapeutics is a
biotechnology company focused on developing and commercializing
novel oncology therapies that target the tumor microenvironment.
Halozyme's lead proprietary program, investigational drug PEGPH20,
applies a unique approach to targeting solid tumors, allowing
increased access of co-administered cancer drug therapies to the
tumor in animal models. PEGPH20 is currently in development for
metastatic pancreatic cancer, non-small cell lung cancer, gastric
cancer, metastatic breast cancer and has potential across
additional cancers in combination with different types of cancer
therapies. In addition to its proprietary product portfolio,
Halozyme has established value-driving partnerships with leading
pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen,
AbbVie and Lilly for its ENHANZE® drug-delivery
technology. Halozyme is headquartered in San Diego. For more information visit
www.halozyme.com.
Contacts:
Jim
Mazzola
858-704-8122
ir@halozyme.com
Chris Burton
858-704-8352
ir@halozyme.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-therapeutics-to-present-at-upcoming-healthcare-conferences-300464185.html
SOURCE Halozyme Therapeutics, Inc.